Wearable Monitoring for Young Children With Spinal Muscular Atrophy
Part of Brain & nervous system clinical trials.
This study uses wearable devices (like smartwatches or activity trackers) to monitor movement and motor development in young children with spinal muscular atrophy (SMA), a rare genetic condition affecting muscle strength. The goal is to see if wearables can track disease progression and treatment response better than traditional clinic visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child has a genetic diagnosis of SMA confirmed by testing, with known SMN2 copy number
- Child is between 4 months and under 4 years old at the start of the study
- Parent or legal guardian can give written permission for participation
- Child does not have other acute or chronic conditions that would interfere with motor assessments
- Child is not currently enrolled in another experimental treatment study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a virtual reality rehabilitation program for young people with SMA (spinal muscular atrophy, a genetic muscle-weakening condition). Researchers want to understand if VR-based exercises can help improve function and quality of life.
This study remotely tracks motor development in children with Duchenne muscular dystrophy or spinal muscular atrophy who were diagnosed at birth or before symptoms started. It aims to see if early monitoring helps improve long-term care and outcomes.
This study watches how people with certain muscle or nerve diseases walk over time. It may help doctors understand changes in walking patterns and is open to adults who can walk and have a genetic diagnosis of a neuromuscular condition.
This study tests a portable device that analyzes walking without markers. It aims to see if it can help assess walking in people with neuromuscular diseases and healthy volunteers, which could lead to simpler check-ups.
This trial tests a new medicine called EXG001-307 for babies with spinal muscular atrophy (SMA) types 1 and 2. The goal is to see if it is safe and helps with muscle strength and breathing.
This study uses remote technology, like apps or wearable devices, to monitor motor skills and development in boys with Duchenne muscular dystrophy (DMD). It aims to find better ways to measure how the disease progresses over time without requiring frequent clinic visits.
Hear when a new Spinal Muscular Atrophy (SMA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.